Welcome to our dedicated page for Strata Skin Sciences news (Ticker: SSKN), a resource for investors and traders seeking the latest updates and insights on Strata Skin Sciences stock.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) is a medical technology company focused on in-office dermatologic devices, and its news flow reflects that specialization. Company announcements frequently highlight developments related to its core technologies: the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClearX® Acne Therapy System. These updates often cover new clinical evidence, regulatory milestones, reimbursement decisions, and commercial expansion in dermatology markets.
Investors and clinicians following SSKN news can expect regular coverage of peer-reviewed studies involving XTRAC in conditions such as psoriasis, vitiligo, atopic dermatitis, and mycosis fungoides, including combination regimens with topical drugs and JAK inhibitors. STRATA frequently reports on published data that it believes support the safety, efficacy, and personalized use of excimer laser therapy across a range of inflammatory and autoimmune skin diseases.
News items also address reimbursement and policy developments. STRATA has issued releases on CMS Medicare Physician Fee Schedule decisions related to CPT® codes 96920–96922, including continued coverage, payment levels, and recognition of future code descriptor expansions for excimer laser procedures. These updates are relevant for understanding how reimbursement may influence utilization of XTRAC in U.S. dermatology clinics.
Corporate and capital markets updates are another recurring theme. STRATA uses news releases to communicate quarterly financial results, non-GAAP performance metrics, registered direct offerings, and at-the-market equity programs. The company also reports on its legal and competitive positioning, including litigation milestones against competing device manufacturers and the recapture of dermatology clinics into its XTRAC partnership network.
International growth initiatives, such as COFEPRIS clearance for TheraClearX in Mexico and partnerships with commercialization firms like MINO Labs, appear in STRATA’s news as the company expands its device-based acne and phototherapy offerings beyond the United States. For users of this SSKN news page, the feed provides an ongoing view into STRATA’s clinical, regulatory, commercial, and financial developments in the dermatology device space.
STRATA Skin Sciences (NASDAQ: SSKN) plans to release its third quarter 2021 financial results on November 10, 2021, after market close. A conference call for a financial review and corporate update will follow at 4:30 p.m. Eastern Time. STRATA specializes in developing innovative dermatologic products, including XTRAC and Pharos excimer lasers, aimed at treating over 31 million patients in the U.S. with conditions like psoriasis and vitiligo. Interested parties can access the call through the company's website or by phone using conference ID 10017028.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced the appointment of Christopher Lesovitz as Chief Financial Officer, effective October 16, 2021, succeeding Matthew Hill. Lesovitz previously served as the company's Controller and has extensive experience in finance within the dermatology sector. Additionally, STRATA has completed an $8 million financing agreement with MidCap Financial Trust, allowing full drawdown of funds to address existing debts, including a loan from Israel Discount Bank and an Economic Injury Disaster Loan.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has been invited to present at the Fall Harvest – Best Ideas from the Buy-Side conference on October 6, 2021, at 11:00 AM ET. CEO Robert J. Moccia will lead the presentation, and one-on-one meetings will be available. Interested parties can access the live and archived webcast via the company’s website. STRATA specializes in innovative dermatologic treatments, including excimer lasers for psoriasis and vitiligo, impacting over 31 million patients in the U.S.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced its participation in two upcoming investor conferences. Management will present at the H.C Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 am ET, and at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 20 at 3:45 pm ET. Webcasts of both presentations will be accessible on the Company's website. STRATA specializes in dermatology technology, offering products like the XTRAC and Pharos lasers for treating conditions such as psoriasis and vitiligo, impacting over 31 million patients in the U.S.
STRATA Skin Sciences (NASDAQ: SSKN) reported strong financial results for the second quarter of 2021, with total revenue of $7.4 million, an 83.1% increase year-over-year. Recurring revenue rose 95.0% to $5.5 million, driven by gross domestic recurring billings of $5.5 million, up 196.6% from the previous year. Gross margins improved to 64.5%. The company concluded the quarter with 889 XTRAC devices installed, marking an increase. Despite a decline in cash reserves to $17 million, the acquisition of Ra Medical's dermatology business is expected to bolster revenue growth.
STRATA Skin Sciences (NASDAQ: SSKN) announced its acquisition of Ra Medical's U.S. dermatology business for approximately $3.7 million. This strategic move positions STRATA as a leading provider in the $6 billion U.S. chronic skin disease treatment market.
The acquisition adds over 400 dermatology practices to STRATA's customer base, significantly enhancing its potential for recurring revenue growth. STRATA expects to see an increase in service contract revenue while integrating Ra Medical's customers into its business model.
STRATA Skin Sciences (NASDAQ: SSKN) plans to announce its Q2 2021 financial results on August 16, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and provide a corporate update. STRATA focuses on innovative dermatology technologies, including the XTRAC® excimer laser for treating conditions like psoriasis and vitiligo, affecting over 31 million patients in the U.S. DTC advertising and in-house support teams help drive patient volume for its partner clinics.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has appointed Brent Cowgill as Vice President of Marketing, enhancing its focus on dermatology products. With over 20 years of experience in healthcare marketing, Cowgill aims to expand STRATA’s market presence and build on the success of its leading XTRAC excimer laser technology. This strategic hire aligns with STRATA’s priority to boost commercial execution and strengthen marketing efforts for its innovative dermatological solutions, which serve over 31 million patients in the U.S.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced its participation in the Oppenheimer MedTech, Tools & Diagnostics Summit on May 26, 2021. The presentation will be available on-demand, showcasing the company's innovative dermatologic treatment technologies like the XTRAC® excimer laser and VTRAC® lamp systems. These products target conditions affecting over 31 million patients in the U.S., including psoriasis and vitiligo. STRATA employs a Direct to Consumer advertising model to boost awareness and support its partner dermatology clinics.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) reported Q1 2021 financial results with total revenue of $5.8 million, down 13.4% from Q1 2020. Recurring revenue decreased 17.9% to $4.7 million. Gross margins also fell 1.7% to 63.7%. Cash reserves slightly decreased to $17.5 million from $18.1 million at year-end 2020. The company's CEO noted ongoing impacts from COVID-19 affecting patient access and revenue recognition. Notably, the global recurring revenue installed base grew to 871 XTRAC devices.
FAQ
What is the current stock price of Strata Skin Sciences (SSKN)?
What is the market cap of Strata Skin Sciences (SSKN)?
